Tender detail
Non-exclusive discount agreement for Guselkumab 100 mg medicine
Summary
DAK-Gesundheit is seeking a non-exclusive medicine discount agreement for the active ingredient guselkumab, limited to the 100 mg strength (ATC L04AC16). The agreement will run from 1 December 2026 to 31 March 2027, or end earlier if an exclusive agreement takes effect.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.